Activation energy in particle suspensions

Assuming that the molar activation energy in a fluid is interpreted as a measure of the potential energy barrier required for the molecular movement [1], the viscosity of a fluid depends on the actual size of the molecules, and the presence of solid particles in a suspension increases the dissipation of energy when the system flows, therefore it is expected that the viscosity of the suspension is higher than that of the pure solvent at a given temperature. The dependence of the viscosity of some silica/glycol suspensions with the temperature can be fitted using an empirical function analogous to the Arrhenius equation, ln⁡η=E/RT-ln⁡C, where η is the viscosity, C is a system-dependent constant, E is the molar activation energy for the viscous flow, T is the absolute temperature and R is the gas universal constant. When the temperature of the suspension decreases two effects are observed. First, larger aggregates of particles are formed due to the reduction of the thermal agitation and, second, the number of links among the molecules of the liquid phase increases. These two effects give place to a higher increase in the viscosity with the temperature compared to the pure solvent. Assuming that a higher viscosity value is due to a smaller free volume available for the molecular movement, and taking into account that the free suspension volume is limited only to the liquid fraction [2], it should be expected that the viscosity of the suspension is less sensitive to temperature than that of the pure solvent. In this work the dependence on the temperature of the viscosity values of the silica/glycol suspensions is compared to that of the liquid media. The results have shown a lower activation energy when the solid volume fraction increases, which has been explained with a scheme that assumes that the particle links are less sensitive to thermal energy absorption than the joining bonds among the solvent molecules. Our conclusion is that, for a given mechanical energy applied to the system, the thermal energy absorbed by the system is mainly used in the rupture of bonds between the solvent molecules. This study can be useful to understand the mechanisms that govern the differences in the activation energy values found between samples of foods, in which many factors are connected with sample composition [3]. [1] Briscoe B, Luckham P, Zhu S. Rheological properties of poly (ethylene oxide) aqueous solutions. J Appl Polym Sci 70 (1998) 419-429. [2] Shenoy AV. Rheology of filled polymer systems. Kluwer Acad Pub, 1999, The Netherlands. [3] Alvarez MD, Canet W. Time-independent and time-dependent rheological characterization of vegetable-based infant purees. J Food Eng 114 (2013) 449-464.Universidad de Málaga, Campus de Excelencia Internacional Andalucía Tech

The clinical safety of disabled patients: proposal for a methodology for analysis of health care risks and specific measures for improvement

The clinical risks associated with health care have been a known factor since ancient times, and their prevention has constituted one of the foundations of health care. However, concern for the risks involved in health care treatments has risen very significantly in recent years, becoming a modern current of concern for clinical health care risks which is referred to by the name of "patient safety" in the scientific literature. Unfortunately, there are no studies on patient safety in dental practice or case studies of adverse events in this practice. In addition to the lack of studies on adverse events in regular dental practice, there are even fewer references to treatment for disabled patients. In this article, we provide a "proposal for analysis" of the clinical risks associated with treating disabled patients, which will make it possible to evaluate the health care risks associated with the treatment of patients who have a specific disability, at one determined moment and in one specific environment

Molecular Mechanisms in Fetal Myocardial Affection Induced by Gestational Diabetes Mellitus: A Literature Review

Introducción: La Diabetes Mellitus Gestacional (DMG) es una condición metabólica compleja que afecta la salud materna y fetal, la cuál a incrementado su diagnóstico en los últimos años. Se ha asociado con anomalías cardiacas fetales (ACF), por lo que es fundamenteal conocer las bases moleculares de su desarrollo. Objetivo: Analizar literatura científica actual, para identificar mecanismos y vías moleculares clave implicados en la afección miocárdica fetal. Metodología: Consulta de bases de datos Pubmed, Scopus y Web of Science. Las publicaciones consideradas fueron del periodo 2019-2024 y excluyendo artículos que analizaran alteraciones cardíacas fetales no relacionadas con DMG. Resultados: Se reconocieron genes, mecanismos y vías moleculares, así como mecanismos clave en la morfogénesis cardíaca, particularmente vías relacionadas con la hiperglucemia e hiperinsulinemia, desregulación de factores de crecimiento, de genes encargados del desarrollo miocárdico, que conducen a ACF.Conclusión: La hiperglucemia e hiperinsulinemia materna y fetal, conducen a modificación de la expresión de genes y crecimiento celular miocárdico en la ACF  asociada con DMG.Introduction: Gestational Diabetes Mellitus (GDM) is a complex metabolic condition that affects maternal and fetal health, particularly associated with functional anomalies in the fetal myocardium. This has increased interest in understanding the molecular bases of the condition. Objective: To analyze the current scientific literature to identify key molecular mechanisms involved in fetal myocardial affection. Methodology: PubMed, Scopus, and Web of Science databases were consulted, considering publications from the period 2019-2024. Articles addressing fetal cardiac complications unrelated to GDM were excluded. Results: Key molecular mechanisms in cardiac morphogenesis were identified, particularly pathways related to maternal and fetal hyperglycemia and hyperinsulinemia, such as mTOR, AKT, ERK, overexpression of TNNI3K and PK2M, deregulation of factors like IGF-1, TGFβ1, and Wnt/β-catenin, as well as increased reactive oxygen species (ROS) leading to cardiac hypertrophy. Conclusion: The results indicate that maternal hyperglycemia and hyperinsulinemia induce modifications in gene expression and abnormal fetal myocardial cell growth in relation to GDM, with preventive and therapeutic implications

Increased hypothalamic anti‐inflammatory mediators in non‐diabetic insulin receptor substrate 2‐deficient mice

© 2021 by the authors.Insulin receptor substrate (IRS) 2 is a key mediator of insulin signaling and IRS-2 knockout (IRS2−/−) mice are a preclinical model to study the development of diabetes, as they develop peripheral insulin resistance and beta-cell failure. The differential inflammatory profile and insulin signaling in the hypothalamus of non-diabetic (ND) and diabetic (D) IRS2−/− mice might be implicated in the onset of diabetes. Because the lipid profile is related to changes in inflammation and insulin sensitivity, we analyzed whether ND IRS2−/− mice presented a different hypothalamic fatty acid metabolism and lipid pattern than D IRS2−/− mice and the relationship with inflammation and markers of insulin sensitivity. ND IRS2−/− mice showed elevated hypothalamic anti-inflammatory cytokines, while D IRS2−/− mice displayed a proinflammatory profile. The increased activity of enzymes related to the pentose-phosphate route and lipid anabolism and elevated polyunsaturated fatty acid levels were found in the hypothalamus of ND IRS2−/− mice. Conversely, D IRS2−/− mice have no changes in fatty acid composition, but hypothalamic energy balance and markers related to anti-inflammatory and insulin-sensitizing properties were reduced. The data suggest that the concurrence of an anti-inflammatory profile, increased insulin sensitivity and polyunsaturated fatty acids content in the hypothalamus may slow down or delay the onset of diabetes.This work was supported by the Spanish Ministry of Science and Innovation with the help of European FEDER funding (grant numbers FIS PI19/00166, BFU 2017-82565-C2-1-R, and RTI2018-094052-B-100), Comunidad de Madrid, Spain (S2017/BMD-3684) and the Network Center for Biomedical Research on Obesity and Nutrition (CIBEROBN) and Diabetes (CIBERDEM) Instituto Carlos III. S.C. was supported by CIBEROBN and A.G.M. by Fundación para la Investigación Biomédica Hospital Infantil Universitario Niño Jesús

Case report: Challenges and implications of conduction system pacing in pediatrics: Case series

Cardiac electrical stimulation in children usually is needed in the setting of complete congenital atrioventricular block, atrioventricular block after heart surgery, and bradycardia associated with some specific channelopathies. In cases of atrioventricular block, the high percentage of ventricular stimulation raises concern on the deleterious effects of chronic stimulation of the right ventricle. In recent years, physiologic stimulation has developed as a valid approach for adult patients and a great interest has risen in offering conduction system pacing also to the pediatric population. We present three pediatric cases of stimulation of the conduction system (His bundle or left bundle branch), in order to show the intrinsic particularities and challenges implied in these new techniques

Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

Background: The PEARL study showed that palbociclib plus endocrine therapy (palbociclib/ET) was not superior to capecitabine in improving progression-free survival in postmenopausal patients with metastatic breast cancer resistant to aromatase inhibitors, but was better tolerated. This analysis compared patient-reported outcomes. Patients and methods: The PEARL quality of life (QoL) population comprised 537 patients, 268 randomised to palbociclib/ET (exemestane or fulvestrant) and 269 to capecitabine. Patients completed the European Organisation for Research and Treatment of Cancer QLQC30 and QLQ-BR23 and EQ-5D-3L questionnaires. Changes from the baseline and time to deterioration (TTD) were analysed using linear mixed-effect and stratified Cox regression models, respectively. Results: Questionnaire completion rate was high and similar between treatment arms. Significant differences were observed in the mean change in global health status (GHS)/QoL scores from the baseline to cycle 3 (2.9 for palbociclib/ET vs.-2.1 for capecitabine (95% confidence interval [CI], 1.4-8.6; P = 0.007). The median TTD in GHS/QoL was 8.3 months for palbociclib/ET versus 5.3 months for capecitabine (adjusted hazard ratio, 0.70; 95% CI, 0.55-0.89; P = 0.003). Similar improvements for palbociclib/ET were also seen for other scales as physical, role, cognitive, social functioning, fatigue, nausea/vomiting and appetite loss. No differences were observed between the treatment arms in change from the baseline in any item of the EQ-5D-L3 questionnaire as per the overall index score and visual analogue scale. Conclusion: Patients receiving palbociclib/ET experienced a significant delay in deterioration of GHS/QoL and several functional and symptom scales compared with capecitabine, providing additional evidence that palbociclib/ET is better tolerated. Trial registration number: NCT02028507 (ClinTrials.gov). EudraCT study number: 2013-003170-27. 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Zoonotic "Enterocytozoon bieneusi" genotypes in free-ranging and farmed wild ungulates in Spain

Microsporidia comprises a diverse group of obligate, intracellular, and spore-forming parasites that infect a wide range of animals. Among them, Enterocytozoon bieneusi is the most frequently reported species in humans and other mammals and birds. Data on the epidemiology of E. bieneusi in wildlife are limited. Hence, E. bieneusi was investigated in eight wild ungulate species present in Spain (genera Ammotragus, Capra, Capreolus, Cervus, Dama, Ovis, Rupicapra, and Sus) by molecular methods. Faecal samples were collected from free-ranging (n = 1058) and farmed (n = 324) wild ungulates from five Spanish bioregions. The parasite was detected only in red deer (10.4%, 68/653) and wild boar (0.8%, 3/359). Enterocytozoon bieneusi infections were more common in farmed (19.4%, 63/324) than in wild (1.5%, 5/329) red deer. A total of 11 genotypes were identified in red deer, eight known (BEB6, BEB17, EbCar2, HLJD-V, MWC_d1, S5, Type IV, and Wildboar3) and three novel (DeerSpEb1, DeerSpEb2, and DeerSpEb3) genotypes. Mixed genotype infections were detected in 15.9% of farmed red deer. Two genotypes were identified in wild boar, a known (Wildboar3) and a novel (WildboarSpEb1) genotypes. All genotypes identified belonged to E. bieneusi zoonotic Groups 1 and 2. This study provides the most comprehensive epidemiological study of E. bieneusi in Spanish ungulates to date, representing the first evidence of the parasite in wild red deer populations worldwide. Spanish wild boars and red deer are reservoir of zoonotic genotypes of E. bieneusi and might play an underestimated role in the transmission of this microsporidian species to humans and other animal

Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

Background: The PEARL study showed that palbociclib plus endocrine therapy (palbociclib/ET) was not superior to capecitabine in improving progression-free survival in postmenopausal patients with metastatic breast cancer resistant to aromatase inhibitors, but was better tolerated. This analysis compared patient-reported outcomes. Patients and methods: The PEARL quality of life (QoL) population comprised 537 patients, 268 randomised to palbociclib/ET (exemestane or fulvestrant) and 269 to capecitabine. Patients completed the European Organisation for Research and Treatment of Cancer QLQ-C30 and QLQ-BR23 and EQ-5D-3L questionnaires. Changes from the baseline and time to deterioration (TTD) were analysed using linear mixed-effect and stratified Cox regression models, respectively. Results: Questionnaire completion rate was high and similar between treatment arms. Significant differences were observed in the mean change in global health status (GHS)/QoL scores from the baseline to cycle 3 (2.9 for palbociclib/ET vs. -2.1 for capecitabine (95% confidence interval [CI], 1.4–8.6; P = 0.007). The median TTD in GHS/QoL was 8.3 months for palbociclib/ET versus 5.3 months for capecitabine (adjusted hazard ratio, 0.70; 95% CI, 0.55–0.89; P = 0.003). Similar improvements for palbociclib/ET were also seen for other scales as physical, role, cognitive, social functioning, fatigue, nausea/vomiting and appetite loss. No differences were observed between the treatment arms in change from the baseline in any item of the EQ-5D-L3 questionnaire as per the overall index score and visual analogue scale. Conclusion: Patients receiving palbociclib/ET experienced a significant delay in deterioration of GHS/QoL and several functional and symptom scales compared with capecitabine, providing additional evidence that palbociclib/ET is better tolerated. Trial registration number: NCT02028507 (ClinTrials.gov). EudraCT study number: 2013-003170-27. © 2021 The Author(s